Inhaled mRNA vaccine for advanced lung cancer and lung metastases
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an inhaled dry powder vaccine that uses mRNA to help your immune system target cancer cells in the lungs. It is for people with advanced lung cancer or solid tumors that have spread to the lungs, who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced lung cancer (without certain genetic changes) or another advanced solid tumor that has spread to the lungs, and standard treatments did not work or are not available.
- You have at least one tumor that can be measured on scans.
- You are well enough to be up and about at least half of the day (ECOG 0 or 1).
- You do not have certain serious lung conditions like COPD, asthma, or interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called MHB036C combined with other anti-tumor treatments for people with advanced lung cancer or other solid tumors that have not responded to standard therapies. It aims to find a safe and effective dose and see if the combination can shrink tumors.
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
This trial tests an inhaled mRNA immunotherapy for people with advanced lung cancer or solid tumors that have spread to the lungs. It might help if standard treatments no longer work or aren't available.
This trial tests a personalized mRNA cancer vaccine (RH125) for people with advanced solid tumors that have spread or cannot be removed by surgery. It may be an option if standard treatments have stopped working or are not suitable, and for some, it will be given with a PD-1 blocker.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.